LitAlert ~~ GeneLit.com

    • Unselected Population Genetic Testing for Personalised Ovarian Cancer Risk Prediction: A Qualitative Study Using Semi-Structured Interviews.
    • Gaba F, Oxley S, Liu X, Yang X, Chandrasekaran D, Kalsi J, Antoniou A, Side L, Sanderson S, Waller J, Ahmed M, Wallace A, Wallis Y, Menon U, Jacobs I, Legood R, Marks D, Manchanda R.
    • Diagnostics (Basel). 2022 Apr 19;12(5):1028. doi: 10.3390/diagnostics12051028.
    • PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers.
    • Luo L, Keyomarsi K.
    • Expert Opin Investig Drugs. 2022 Apr 18. doi: 10.1080/13543784.2022.2067527. Epub ahead of print.
    • Review
    • Screening and risk reducing surgery for endometrial or ovarian cancers in Lynch syndrome: a systematic review.
    • Lim N, Hickey M, Young GP, Macrae FA, Kelly C.
    • Int J Gynecol Cancer. 2022 Apr 18:ijgc-2021-003132. doi: 10.1136/ijgc-2021-003132. Epub ahead of print.
    • BRCA1: An Endocrine and Metabolic Regulator.
    • Werner H.
    • Front Endocrinol (Lausanne). 2022 Mar 31;13:844575. doi: 10.3389/fendo.2022.844575.
    • Validity of Weekly Administration of Carboplatin after Carboplatin-Induced SIADH: Two Case Reports and Literature Review.
    • Fujitsuka S, Horikawa N, Yoshida T, Yu S, Kuroda R, Tsuji M, Umemiya M, Gou R, Inayama Y, Tani H, Kosaka K.
    • Case Rep Oncol. 2022 Mar 3;15(1):156-162. doi: 10.1159/000522153.